879126-98-4

Basic information

• Product Name: Lenalidomide
• CAS NO: 879126-98-4
• Molecular Weight: 259.265
• Mol File: 879126-98-4.mol
• Article Data: 62

Chemical Properties

• CAS DataBase Reference: Lenalidomide(CAS DataBase Reference)
• NIST Chemistry Reference: Lenalidomide(879126-98-4)
• EPA Substance Registry System: Lenalidomide(879126-98-4)

Safety Data

• Hazardous Substances Data: 879126-98-4(Hazardous Substances Data)

Upstream product

• 59382-59-1 2-methyl-3-nitro-benzoic acid methyl ester 
• 56-86-0 L-glutamic acid 
• 24666-56-6 rac-α-aminoglutarimide hydrochloride 
• 98475-07-1 2-bromomethyl-3-nitro-benzoic acid methyl ester 
• 1155-62-0 N-benzyloxycarbonyl-L-glutamic acid 
• 56-85-9 GLUTAMINE 
• 1218991-05-9 glutamine methyl ester 
• 65399-18-0 4-nitrophthalide 
• 21606-04-2 methyl 2-carboxy-3-nitrobenzoate 
• 603-11-2 3-nitrophthalic acid 
• 18583-89-6 methyl 3-amino-2-methylbenzoate 
• 1975-50-4 2-methyl-3-nitrobenzic acid 
• 2353-44-8 (+/-)-α-aminoglutarimide 
• 13726-85-7 Boc-Gln-OH 

Downstream Products

• 847871-99-2 3-(4-amino-1-oxo-1,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione hemihydrate 
• 1421593-80-7 N-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)acetamide 
• 444289-22-9 N-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)benzamide 

Relevant articles and documents

Influence of Linker Attachment Points on the Stability and Neosubstrate Degradation of Cereblon Ligands

Proteolysis targeting chimeras (PROTACs) hijacking the cereblon (CRBN) E3 ubiquitin ligase have emerged as a novel paradigm in drug development. Herein we found that linker attachment points of CRBN ligands highly affect their aqueous stability and neosubstrate degradation features. This work provides a blueprint for the assembly of future heterodimeric CRBN-based degraders with tailored properties.

Method for synthesizing lenalidomide

The invention belongs to the field of chemical synthesis, and particularly relates to a method for synthesizing lenalidomide. The method adopts three-step polymerization, and specifically comprises: (1) carrying out a bromination reaction on 2-methyl-3-nitromethyl benzoate as a starting raw material and a bromination reagent to generate a compound 1 2-bromomethyl-3-nitromethyl benzoate; (2) performing cyclization on the compound 1 and 3-aminopiperidine-2,6-dione hydrochloride under a solvent-free condition to generate a compound 2 3-(4-nitro-1-oxo-1,3-dihydroisoindole-2-yl)piperidine-2,6-dione; and (3) reducing the compound 2 with a reducing agent to obtain lenalidomide. According to the invention, the method is a novel preparation process method of lenalidomide, and has advantages of easily available process raw materials, short steps, simple and convenient operation, environmental friendliness, implementation value of industrial production, and social and economic benefits.

Anhydrous preparation method of lenalidomide

The invention relates to an anhydrous preparation method of lenalidomide. The invention discloses a novel method for preparing a 3-(4-amino-1-oxo-1,3-dihydro-2H-isoindole-2-yl) piperidine-2,6-diketoneanhydrous compound, and belongs to the technical field of chemical synthesis. The process route is short in steps, simple and convenient to operate and mild in reaction conditions, and the finally obtained product is excellent in quality and easy for industrial production.